TSPO PET in neurology: Vivash and O'Brien focus on new developments, current limitations, and potential future directions in PET imaging of translocator protein expression in neuroinflammation.
Page 165
uPAR and glioma imaging: Hirata and Tamaki offer perspective on the potential of urokinase-type plasminogen activator receptor PET imaging in brain cancer and preview an article in this issue of JNM on 2 new uPAR-targeting agents in glioblastoma.
Page 169
Molecular imaging in precision medicine: Ehlerding and Cai describe the potential of multimodality, multiparametric imaging to advance personalized cancer management and preview an article in this issue of JNM using such an approach to assess a drug’s biologic effects.
Page 171
DNA damage in radioiodine therapy: Eberlein and colleagues investigate DNA double-strand break formation and its correlation to absorbed dose to the blood in patients with surgically treated differentiated thyroid cancer undergoing a first radioiodine therapy for remnant ablation.
Page 173
Triple-phase SPECT/CT in NEN: Ruf and colleagues compare the commonly used 3-day somatostatin receptor scintigraphy protocol for gastroenteropancreatic neuroendocrine neoplasms with a more patient-friendly 1-day protocol.
Page 180
68Ga-DOTATATE in head and neck PGLs: Janssen and colleagues compare the clinical utility of 68Ga-DOTATATE PET/CT functional imaging in parasympathetic head and neck paragangliomas with that of anatomic imaging with CT/MR and other functional modalities, including 18F-FDOPA PET/CT.
Page 186
Imaging angiogenesis in PAD: Takagi and colleagues explore the question of whether 99mTc-macroaggregated albumin perfusion scintigraphy can predict quantitated blood flow after therapeutic angiogenesis in patients with peripheral artery disease.
Page 192
PVEC in 18F-florbetaben PET: Rullmann and colleagues ask whether partial-volume effect correction, adjusting for neocortical atrophy bias, improves the accuracy of quantitative 18F-florbetaben β-amyloid brain PET imaging.
Page 198
11C-PiB, 18F-FDG PET, and AD prediction: Grimmer and colleagues compare visual and automated techniques in assessment of amyloid deposition (using11C-PiB PET) and neuronal metabolism (using 18F-FDG PET) and resulting accuracies in predicting Alzheimer disease–associated dementia.
Page 204
18F-THK5351 tau PET tracer: Harada and colleagues detail the development of a novel tau PET tracer designed for imaging neurofibrillary pathology in dementia and describe initial studies in patients with Alzheimer disease.
Page 208
Atlas-based attenuation correction: Sekine and colleagues evaluate a simplified atlas-based attenuation correction method for integrated PET/MR in the human brain by comparing 18F-FDG PET data corrected using either the simplified approach or true CT data.
Page 215
Sex-specific brain changes and aging: Kakimoto and colleagues assess distinctive sex-specific changes in brain glucose metabolism and morphology using MR and 18F-FDG PET imaging during aging in cognitively healthy adults.
Page 221
PET uptake time effect on response: Kurland and colleagues examine the influence of changes in time between tracer injection and 18F-FDG PET image acquisition on tumor response assessment using a virtual clinical trials approach.
Page 226
Arsenic trioxide as radiation sensitizer: Modak and colleagues explore the utility of arsenic trioxide in enhancing the efficacy of 131I-MIBG therapy and test the combination in a trial focusing on recurrent/refractory stage 4 neuroblastoma and metastatic paraganglioma/pheochromocytoma.
Page 231
CT dose in PET/CT: Jallow and colleagues report on diagnostic reference levels of the volumetric CT dose index from sites that conduct whole-body oncologic PET/CT examinations and participated in the scanner validation program of the SNMMI Clinical Trials Network.
Page 238
18F-FIMX modeling: Zanotti-Fregonara and colleagues evaluate the ability of 18F-FIMX PET to quantify metabotropic glutamate receptor 1 in humans and use the relative density of receptor gene transcripts to estimate specific and nondisplaceable uptake in each brain region.
Page 242
CXCR4-directed endoradiotherapy: Herrmann and colleagues summarize first-in-human experience with chemokine receptor 4–directed endoradiotherapy with 177Lu- and 90Y-pentixather in heavily pretreated patients with intramedullary and extensive extramedullary manifestations of multiple myeloma.
Page 248
Gastrointestinal bleeding scintigraphy: Grady provides an educational overview of the diagnostic uses, appropriate methodologies, interpretive criteria, and special considerations for scintigraphic assessment of gastrointestinal bleeding.
Page 252
SSTR agonist vs. antagonist therapy: Dalm and colleagues directly compare the therapeutic effects of 177Lu-DOTA-octreotate, a somatostatin receptor agonist, and 177Lu-DOTA-JR11, a somatostatin receptor antagonist, in both in vitro and in vivo studies.
Page 260
Imaging radiation-induced marrow injury: Rendon and colleagues use 18F-FLT PET/CT to measure cellular proliferation in bone marrow and ultra-small superparamagnetic iron oxide MR imaging to assess radiation-induced vascular damage for “topological mapping” of radiation exposure and damage.
Page 266
uPAR PET in glioblastoma: Persson and colleagues explore the potential of PET imaging of the urokinase-type plasminogen activator receptor in orthotopic xenografted glioblastoma tumors.
Page 272
SPECT and NSC migration: Cheng and colleagues report on a strategy for mesoporous silica nanoparticle–facilitated SPECT tracking of 111In-labeled neural stem cells and describe the potential for integration with MR for multimodal tracking of therapeutic cells to brain malignancies.
Page 279
VEGFR-2 imaging in lung cancer: Luo and colleagues detail synthesis and characterization of Ramucirumab as part of a 64Cu-labeled antibody-based PET agent for imaging vascular endothelial growth factor receptor 2 expression in vivo.
Page 285
Microglial COX-1 in AD: Shukuri and colleagues describe the synthesis of an 11C-labeled PET probe specific for microglial cyclooxygenase-1 and use it to investigate COX-1 changes during Alzheimer disease progression in a mouse model.
Page 291
Cholinesterase visualization in AD: Macdonald and colleagues report on synthesis and evaluation of a cholinesterase-binding ligand, phenyl 4-123I-iodophenylcarbamate, and its potential to image cholinesterase activity associated with brain β-amyloid plaques.
Page 297
Dopamine imaging with 11C-6MemTyr: Kanazawa and colleagues compare this novel PET probe with β-11C-l-DOPA and 6-18F-fluoro-l-DOPA in quantitative imaging of presynaptic dopamine synthesis in the brains of normal and Parkinson disease model monkeys.
Page 303
Imaging metoclopramide transport: Pottier and colleagues use 11C-metoclopramide PET imaging to elucidate the kinetic impact in the brain of metoclopramide exposure on P-glycoprotein transporter function.
Page 309
18F-labeled deuterated fluorodeprenyl: Nag and colleagues describe the development of this novel PET agent and initial evaluation of its potential to visualize and quantify monoamine oxidase B activity in vivo.
Page 315
Molecular imaging of Src inhibition: Gao and colleagues use multiple approaches, including bioluminescence, 18F-FDG PET, integrin αvβ3–targeted SPECT/CT, and vascular endothelial growth factor–targeted near-infrared fluorescence imaging, to guide dasatinib anti-Src therapy and aid in rational therapeutic design.
Page 321
- © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.